Is the Novartis breakthrough gene therapy overpriced or not?

first_img Late last year, Novartis (NVS) began marketing a breakthrough gene therapy for treating youngsters with advanced leukemia and slapped a $475,000 price tag on the one-time treatment. The eye-popping number sparked debate, but the drug was quickly deemed cost effective by a nonprofit watchdog.The controversy is far from over, though. STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Ed Silverman By Ed Silverman Feb. 9, 2018 Reprints What is it? [email protected] Pharmalot Log In | Learn More Is the Novartis breakthrough gene therapy overpriced or not? What’s included?center_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Georgios Kefalas/Keystone/AP Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED @Pharmalot GET STARTED Tags cancerdrug pricingpharmaceuticalsSTAT+ About the Author Reprintslast_img read more